Lexicon Phase 2 Study Of LX1033 In IBS-d Shows Differences Between Placebo and LX1033 were Not Statistically Significant

Lexicon Pharmaceuticals (Nasdaq: LXRX ) today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play